Arcus Biosciences, Inc.

205 articles about Arcus Biosciences, Inc.

• Arcus Biosciences Announces New Employment Inducement Grants - September 26, 2023

  9/26/2023

  Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 33,200 shares of the Company’s common stock at an exercise price per share of $18.66, which was the closing price on September 25, 2023, and restricted stock units to acquire a total of 16,600 shares of the Company’s common stock.

• 

  Why Biopharma Companies Buy Stock in One Another

  9/13/2023

  Biopharma companies buying stock in one another did not used to be an unusual practice, but experts told BioSpace this is becoming less common due to greater market volatility.

• Arcus Biosciences Announces New Employment Inducement Grants - September 11, 2023

  9/11/2023

  Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 35,400 shares of the Company’s common stock at an exercise price per share of $21.38, which was the closing price on September 8, 2023, and restricted stock units to acquire a total of 17,700 shares of the Company’s common stock.

• Arcus Biosciences Announces New Employment Inducement Grants - August 24, 2023

  8/24/2023

  Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 14,600 shares of the Company’s common stock at an exercise price per share of $23.03, which was the closing price on August 23, 2023, and restricted stock units to acquire a total of 7,300 shares of the Company’s common stock.

• Arcus Biosciences to Participate in Multiple Upcoming Investor Conferences

  8/23/2023

  Arcus Biosciences announced that its management team will participate in the following upcoming investor conferences in September.

• Arcus Biosciences Announces New Employment Inducement Grants - August 09, 2023

  8/9/2023

  Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted 11 new employees options to purchase a total of 35,400 shares of the Company’s common stock at an exercise price per share of $18.44, which was the closing price on August 8, 2023, and restricted stock units to acquire a total of 17,700 shares of the Company’s common stock.

• Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update

  8/7/2023

  Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update.

• Arcus Biosciences Announces New Employment Inducement Grants - July 25, 2023

  7/25/2023

  Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 21,200 shares of the Company’s common stock at an exercise price per share of $19.50, which was the closing price on July 24, 2023, and restricted stock units to acquire a total of 10,600 shares of the Company’s common stock.

• Arcus Biosciences Announces New Employment Inducement Grants - July 11, 2023

  7/11/2023

  Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted eight new employees options to purchase a total of 20,600 shares of the Company’s common stock at an exercise price per share of $21.88, which was the closing price on July 10, 2023, and restricted stock units to acquire a total of 10,300 shares of the Company’s common stock.

• Arcus Biosciences Announces New Employment Inducement Grants - June 26, 2023

  6/26/2023

  Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 11,800 shares of the Company’s common stock at an exercise price per share of $19.24, which was the closing price on June 23, 2023, and restricted stock units to acquire a total of 5,900 shares of the Company’s common stock.

• Arcus Biosciences Announces New Employment Inducement Grants - June 09, 2023

  6/9/2023

  Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 11,600 shares of the Company’s common stock at an exercise price per share of $21.64, which was the closing price on June 8, 2023, and restricted stock units to acquire a total of 5,800 shares of the Company’s common stock.

• ASCO: Gilead and Arcus's Cancer Immunotherapy Combo Faces Scrutiny Over Lower Survival Rates

  6/3/2023

• Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

  6/3/2023

  Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations.

• Arcus Biosciences to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

  5/30/2023

  Arcus Biosciences (NYSE:RCUS) announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference at the Waldorf Astoria Monarch Beach Resort & Club in Dana Point, California.

• Arcus Biosciences Announces New Employment Inducement Grants - May 24, 2023

  5/24/2023

  Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted five new employees options to purchase a total of 53,800 shares of the Company’s common stock at an exercise price per share of $18.05, which was the closing price on May 23, 2023, and restricted stock units to acquire a total of 26,900 shares of the Company’s common stock.

• Presentations at the 2023 ASCO Annual Meeting Highlight Arcus Biosciences’ Expanding Portfolio of Investigational Medicines and Late-Stage Studies Across Multiple Types of Cancer

  5/17/2023

  Arcus Biosciences, Inc. today announced seven accepted abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 2-6, 2023.

• Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation

  5/15/2023

  Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases.

• Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update

  5/9/2023

  Arcus Biosciences, Inc. (NYSE:RCUS) today reported financial results for the first quarter ended March 31, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT, the adenosine axis (CD73 and A2a/A2b receptors), HIF-2a and PD-1 – across multiple common cancers.

• Arcus Biosciences Announces New Employment Inducement Grants - May 08, 2023

  5/8/2023

  Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 11,200 shares of the Company’s common stock at an exercise price per share of $19.85, which was the closing price on May 8, 2023, and restricted stock units to acquire a total of 5,600 shares of the Company’s common stock.

• Arcus Biosciences Announces New Employment Inducement Grants - April 25, 2023

  4/25/2023

  Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 17,600 shares of the Company’s common stock at an exercise price per share of $19.31, which was the closing price on April 24, 2023, and restricted stock units to acquire a total of 8,800 shares of the Company’s common stock.